BANDO AIFA 2006;;;;;;;; Link a Progetto e CV;Codice;Responsabile Scientifico; Istituzione;Titolo;Budget Indicato nel Contratto;Budget Ridotto per Riduzione Numerosità Campionaria;Extra Budget Autorizzato per Farmaco o Assicurazione ; http://www.agenziafarmaco.gov.it/sites/default/files/1_AMADORI_DINO.zip;FARM6FJJAY;AMADORI DINO ;Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ;Sequential treatment strategy for metastatic colorectal cancer: a phase III prospective randomized multicenter study of chemotherapy (CT) with or without bevacizumab as first-line therapy followed by two phase III randomized studies of CT alone or CT plus bevacizumab with or without cetuximab as second-line therapy.;950.000,00;852.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/2_AMMASSARI_ADRIANA.zip;FARM637CHK;AMMASSARI ADRIANA ;Istituto Nazionale per le Malattie Infettive Lazzaro SpallanzaniI.R.C.C.S. ;Prospective randomized controlled multi-dimensional trial on an informative and educational program for the appropriate use on antiretroviral drugs focused on patients and patient associations: effect on adherence improvement.;542.500,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/3_ARDIZZONI_ANDREA.zip;FARM6PMFJM;ARDIZZONI ANDREA ;Gruppo Oncologico Italiano di Ricerca Clinica - GOIRC;Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC);240.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/4_BARBUI_TIZIANO.zip;FARM6YNXAN;BARBUI TIZIANO ;Azienda Ospedaliera Ospedali Riuniti Di Bergamo ;Intensity of CYTOreductive therapy to prevent cardiovascular events in patients with Polycythemia vera (PV) – CYTO-PV;300.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/5_BERNARDI_MAURO.zip;FARM6P824B;BERNARDI MAURO ;Università di Bologna “Alma Mater Studiorum”- Dipartimento di Medicina Interna, Cardioangiologia Epatologia;The use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: a multicentric, open-label randomized clinical trial;898.800,00;838.920,00;; http://www.agenziafarmaco.gov.it/sites/default/files/6_BERNI_CANANI_ROBERTO.zip;FARM6FJ728;BERNI CANANI ROBERTO ;Università degli Studi di Napoli “Federico II”- Dip. di Pediatria;Therapeutic efficacy of butyrate in pediatric patients with congenital chloride diarrhea;151.500,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/7_BONATI_MAURIZIO.zip;FARM6Z3KX9;BONATI MAURIZIO ;Istituto di ricerche farmacologiche “Mario Negri”;Prescription, efficacy, and safety of psychotropic drugs in the Italian paediatric population;645.623,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/8_BONINI_STEFANO.zip;FARM6AS8AW;BONINI STEFANO ;Università Campus Bio-Medico di Roma;Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eye drop treatment on patients with ocular cicatricial pemphigoid.;270.000,00;236.252,00;; http://www.agenziafarmaco.gov.it/sites/default/files/9_BORTOLUS_RENATA.zip;FARM6KWTCT;BORTOLUS RENATA ;Azienda Ospedaliera Universitaria Integrata di Verona ;RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF HIGH DOSE OF FOLIC ACID TO PREVENT THE OCCURRENCE OF CONGENITAL MALFORMATIONS.;916.500,00;830.130,00;; http://www.agenziafarmaco.gov.it/sites/default/files/10_CALABRESI_PAOLO.zip;FARM6TT8SP;CALABRESI PAOLO ;Dipartimento di Specialita’ Medico-Chirurgiche e Sanita’ Pubblica;SODIUM VALPROATE IN THE TREATMENT OF MEDICATION OVERUSE HEADACHE:A CONTROLLED RANDOMIZED CLINICAL TRIAL;525.000,00;458.727,00;; http://www.agenziafarmaco.gov.it/sites/default/files/11_CALABR%C3%92_RAFFAELE.zip;FARM6HCEM5;CALABRÒ RAFFAELE ;Seconda Università degli Studi di Napoli;Arterial Hypertension After Successful Aortic Decoarctation: Atenolol vs Enalapril Comparison of Efficacy and Tolerability in Pediatric Age.;168.000,00;142.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/12_CALTAGIRONE_CARLO.zip;FARM6ZEMBP;CALTAGIRONE CARLO ;Fondazione IRCCS Santa Lucia;Mortality of elderly using conventional and non conventional antipsychotic drugs for the behavioral and psychological symptoms of dementia and for other psychical disorders;360.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/13_CASCINU_STEFANO.zip;FARM6XB38F;CASCINU STEFANO ;Fondazione Giscad per la Ricerca sui Tumori ;Open-label randomized, parallel group, phase III, multicentric trial comparing two different sequences of therapy (IRINOTECAN/CETUXIMAB followed by FOLFOX-4 vs FOLFOX-4 followed by IRINOTECAN/CETUXIMAB) in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab as first line chemotherapy;395.250,00;274.780,00;; http://www.agenziafarmaco.gov.it/sites/default/files/14_CICCONE_ALFONSO.zip;FARM6LN3KS;CICCONE ALFONSO ;Azienda Ospedaliera Ospedale Niguarda Ca’ Granda;SYNTHESIS: A RANDOMIZED CONTROLLED TRIAL ON INTRA-ARTERIAL VERSUS INTRAVENOUS THROMBOLYSIS IN ACUTE ISCHEMIC STROKE;550.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/15_CITERIO_GIUSEPPE.zip;FARM6FKJKK;CITERIO GIUSEPPE ;Azienda Ospedaliera S. Gerardodi Monza;Anesthesiological strategies in elective craniotomy: randomized, equivalence, open trial;551.880,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/16_CONTE_PIERFRANCO.zip;FARM62MC97;CONTE PIERFRANCO ;Università degli Studi di Modena ;Short-HER: multicentric randomised phase III trial of adjuvant chemotherapy plus 3 vs 12 months of trastuzumab in breast cancer patients with HER2 positive disease;1.614.600,00;1.459.620,00;; http://www.agenziafarmaco.gov.it/sites/default/files/17_CORCHIA_CARLO.zip;FARM6NJ3TZ;CORCHIA CARLO ;Ospedale pediatrico “Bambino Gesù”;Double blind randomized controlled study on the benefit-risk profile of the administration of Sildenafil (Viagra®) in the treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension;240.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/18_CORRADO_ANTONIO.zip;FARM6YHYW4;CORRADO ANTONIO ;Azienda Ospedaliero-Universitaria Careggi Firenze ;LONG-TERM OXYGEN THERAPY (LTOT) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS WITH MODERATE CHRONIC HYPOXEMIA AND CHRONIC HEART FAILURE;1.133.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/19_DEL_MASTRO_LUCIA.zip;FARM6N78KN;DEL MASTRO LUCIA ;Istituto Nazionale per la Ricerca sul Cancro;EFFICACY AND TOXICITY OF TRASTUZUMAB AT THE MAINTAINING DOSE OF 1 MG/KG/WEEK VS THE STANDARD DOSE OF 2 MG/KG/WEEK IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC BREAST CANCER PATIENTS. A PHASE III MULTICENTER STUDY.;608.850,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/20_DI_ROCCO_MAJA.zip;FARM6JBLZ2;DI ROCCO MAJA ;Istituto “Gaslini” Genova;Multicenter randomized study to assess the efficacy and the safety of two therapeutic regimens(high dose of imiglucerase versus co-administration of imiglucerase and miglustat) in type I Gaucher disease patients who have not responded to previous treatment with low dose imiglucerase;171.750,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/21_FALDELLA_GIACOMO.zip;FARM63TMS3;FALDELLA GIACOMO ;Azienda Ospedaliero Universitaria Policlinico S. Orsola Malpighi;EFFICACY AND SAFETY OF CONTINUOUS INFUSION OF FENTANYL FOR PAIN CONTROL IN PRETERM NEWBORNS ON MECHANICAL VENTILATION;200.000,00;130.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/22_FIORILLI_MASSIMO.zip;FARM6KMZFY;FIORILLI MASSIMO ;Università “La Sapienza” Roma Dipartimento Di Medicina Clinica;EVALUATION OF THE BENEFIT/COST/SAFETY PROFILE OF LOW-DOSE ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB) TREATMENT FOR REFRACTORY MIXED CRYOGLOBULINEMIA;240.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/23_FRATICELLI_PAOLO.zip;FARM69JAJ9;FRATICELLI PAOLO ;Azienda Ospedaliero UniversitariaOspedali Riuniti “Umberto I G.M. Lancisi – G. Salesi;Low-dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: a Phase II pilot study.;250.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/24_GASPARINI_GIAMPIETRO.zip;FARM6L9TFK;GASPARINI GIAMPIETRO ;Collegio Italiano dei Primari Oncologi Medici OspedalieriGenova ;A RANDOMIZED TRANSLATIONAL PHASE III STUDY: OPTIMIZATION OF THE FOLFIRI SCHEDULE IN COMBINATION WITH BEVACIZUMAB FOR THERAPY OF METASTATIC COLORECTAL CANCER (MCC), BASED ON THE GENETIC POLIMORPHISMS (PHARMACOGENETIC EVALUATION) AND ANALYSIS OF CIRCULATING BIOMARKERS. STUDY COORDINATED BY THE C.I.P.O.M.O. ASSOCIATION;383.666,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/25_GATTINONI_LUCIANO.zip;FARM6JS3R5;GATTINONI LUCIANO ;"Fondazione Irccs – Ca’ Granda Ospedale Maggiore Policlinico Mangiagalli Regina Elena ";Efficacy of albumin administration for volume replacement in patients with severe sepsis or septic shock;1.098.300,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/26_LANDONI_GIOVANNI.zip;FARM6H73Z9;LANDONI GIOVANNI ;Fondazione Centro San Raffaele del Monte Tabor;Cardiac protection by Sevoflurane in high risk patients undergoing cardiac surgery. A randomized controlled study.;105.725,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/27_MAZZAGLIA_GIAMPIERO.zip;FARM6JNEAM;MAZZAGLIA GIAMPIERO ;Agenzia Regionale di Sanità Firenze;Assessing the risk/benefit profile of bisphosphonates therapy in the secondary prevention of osteoporotic fractures: results from a retrospective cohort study with regional claims databases.;577.500,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/28_MORETTI_COSTANZO.zip;FARM6XAXBR;MORETTI COSTANZO ;Dipartimento di Medicina dei Sistemi – Universita’ Degli Studi Di Roma Tor Vergata ;Multicenter, randomized, double masked, controlled study on efficacy and safety of bicalutamide treatment in patients affected by familiar polycystic ovary syndrome (PCOS);299.370,00;270.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/29_PALMIERI_GIOVANNELLA.zip;FARM6HJ7CA;PALMIERI GIOVANNELLA ;Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica dell’Università degli Studi di Napoli Federico II;Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours (TET) or Histiocitosi X (LCH) with Imatinib Mesylate.;229.500,00;163.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/30_PAPI_ALBERTO.zip;FARM6BWSF9;PAPI ALBERTO ;Universita’ degli Studi di Ferrara;P.r.n. budesonide/formoterol combination versus regular budesonide/formoterol combination plus prn terbutaline in mild-moderate persistent asthma;1.109.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/31_PARODI_OBERDAN.zip;FARM659PTX;PARODI OBERDAN ;Azienda Ospedaliera Ospedale Niguarda Ca’ Granda;Effects of tetrahydrobiopterin (BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial;267.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/32_PESCI_ALBERTO.zip;FARM693KLZ;PESCI ALBERTO ;Università degli Studi di Milano-Bicocca;Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial.;294.600,00;265.120,00;; http://www.agenziafarmaco.gov.it/sites/default/files/33_PIERANNUNZIO_DANIELA.zip;FARM6F47Z4;PIERANNUNZIO DANIELA ;Istituto Superiore di Sanita’;Implementation and evaluation of a training programme on orphan drugs targeting patients’ associations and families of patients with rare diseases.;180.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/34_PUCCI_NERI.zip;FARM6FYZB3;PUCCI NERI ;Azienda Ospedaliero-Universitaria “A. Meyer” Firenze;MULTICENTRIC COMPARATIVE RANDOMIZED DOUBLE BLIND CROSS OVER STUDY WITH TACROLIMUS (FK506)0.1% EYEDROPS AND CYCLOSPORINE 1% EYEDROPS IN CHILDREN WITH SEVERE ACTIVE VERNAL KERATOCONJUNCTIVITIS, LASTING 7 WEEKS, FOLLOWED BY AN OPEN TRIAL LASTING 24 MONTHS TO EVALUATE LONG TERM EFFICACY AND SAFETY OF THE TREATMENT;160.000,00;155.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/35_RAMBALDI_ALESSANDRO.zip;FARM6223SS;RAMBALDI ALESSANDRO ;Azienda Ospedaliera Ospedali Riuniti Di Bergamo;"Randomized study comparing intravenous Busulfan (I.V. Bu; Busilvex®) plus Cyclophosphamide (BuCy2) versus intravenous Busulfan plus Fludarabine (BuFlu) as conditioning regimens prior to allogeneic hematopoietic stem cell transplantation in patients with Acute Myeloid Leukemia, Chronic Myeloid Leukemia and Myelodysplastic Syndrome";250.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/36_RAMBALDI_ALESSANDRO.zip;FARM6YMY2N;RAMBALDI ALESSANDRO EX BASSAN RENATO ;Azienda Ospedaliera Ospedali Riuniti Di Bergamo;A multicentric randomized trial in adult patients with acute myelogenous leukemia (AML), to compare 1) a standard-dose versus high-dose remission induction regimen, and 2) an autologous blood stem cell transplantation versus an autologous blood stem cell-supported multicycle high-dose chemotherapy program,within a risk-oriented postremission strategy reserving allogeneic stem cell transplantation for high-risk cases;200.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/37_RASCHETTI_ROBERTO.zip;FARM68SY5C;RASCHETTI ROBERTO ;Istituto Superiore di Sanita’;Alzheimer's Disease (AD) and antipsychotics: a long term, multicentre, double blind, randomised clinical trial;1.950.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/38_REDAELLI_TIZIANA.zip;FARM6Y35XM;REDAELLI TIZIANA ;Azienda Ospedaliera OspedaleNiguarda Ca’ Granda;EVALUATION OF THE TOLERABILITY AND EFFICACY OF ERYTHROPOIETIN (EPO) TREATMENT IN SPINAL SHOCK: COMPARATIVE STUDY VS METHYLPREDNISOLONE (MP);259.500,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/39_REMUZZI%20GIUSEPPE.zip;FARM6WE4PP;REMUZZI GIUSEPPE EX MINGARDI GIULIO ;Istituto di Ricerche Farmacologiche Mario Negri;A PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED END-POINT (PROBE) TRIAL TO EVALUATE WHETHER, AT COMPARABLE BLOOD PRESSURE CONTROL, ACE INHIBITOR THERAPY MORE EFFECTIVELY THAN NON RAS INHIBITOR THERAPY REDUCES CARDIOVASCULAR MORBIDITY AND MORTALITY IN CHRONIC HEMODIALYSIS PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY;828.170,00;577.335,00;; http://www.agenziafarmaco.gov.it/sites/default/files/40_RICCARDI_GABRIELE.zip;FARM6T9CET;RICCARDI GABRIELE ;Societa’ Italiana di Diabetologia;EFFECTS OF THE ADDITION OF A THIAZOLIDINEDIONE AS COMPARED WITH A SULFONYLUREA ON THE INCIDENCE OF MACROVASCULAR EVENTS IN TYPE 2 DIABETIC PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN;2.400.000,00;2.146.048,00;; http://www.agenziafarmaco.gov.it/sites/default/files/41_SCANNI_ALBERTO.zip;FARM6F5JER;SCANNI ALBERTO ;Azienda Ospedaliera Fatebenefratelli e Oftalmico;Optimization of erlotinib for the treatment of patients with advanced non-small cell lung cancer: an Italian randomized trial;1.772.370,00;1.264.622,00;; http://www.agenziafarmaco.gov.it/sites/default/files/42_SCARPA_MAURIZIO.zip;FARM6J8WS4;SCARPA MAURIZIO ;"Dipartimento di Pediatria “Salus Pueri""";EVALUATION OF THE EFFICACY OF ENZYME REPLACEMENT THERAPY IN PEDIATRIC PATIENTS AFFECTED BY MUCOPOLYSACCHARIDOSIS TYPE II (HUNTER SYNDROME);223.200,00;198.333,00;; http://www.agenziafarmaco.gov.it/sites/default/files/43_SORGE_GIOVANNI.zip;FARM6CC747;SORGE GIOVANNI ;Azienda Ospedaliero Universitaria Policlinico di Catania ;Evaluation of enzyme replacement therapy with Naglazyme (Aryplase) on joint disease in mucopolysaccharidosis type VI patients.;50.000,00;;;* http://www.agenziafarmaco.gov.it/sites/default/files/44_TARONI_FRANCO.zip;FARM6H95MJ;TARONI FRANCO ;Fondazione IRCCS IstitutoNeurologico “Carlo Besta”;Randomized placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in adult patients with Friedreich’s ataxia (a pilot study);259.600,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/45_TERZOLO_MASSIMO.zip;FARM65BEM9;TERZOLO MASSIMO ;Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino ;EFFICACY OF ADJUVANT MITOTANE TREATMENT IN PROLONGING DISEASE-FREE SURVIVAL IN PATIENTS WITH ADRENOCORTICAL CARCINOMA SUBMITTED TO RADICAL RESECTION;300.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/46_TOGNONI_GIOVANNI.zip;FARM6X822T;TOGNONI GIANNI ;Consorzio Mario Negri Sud;Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSe of Erythropoietins (DOSE) trial;2.377.440,00;1.430.000,00;; http://www.agenziafarmaco.gov.it/sites/default/files/47_TONI_DANILO.zip;FARM65KNKY;TONI DANILO ;Dipartimento Di Scienze Neurologiche – Universita ’“La Sapienza” di Roma ;A randomized controlled trial of alteplase (rt-PA) vs standard treatment in acute ischemic hemispheric stroke in patients aged more than 80 years, where thrombolysis is initiated within 3 hours after stroke onset;833.526,00;;90.450,00; http://www.agenziafarmaco.gov.it/sites/default/files/48_VANNUCCHI_ALESSANDRO.zip;FARM6AKR9W;VANNUCCHI ALESSANDRO ;Università degli Studi di Firenze, Dipartimento di Area Critica Medico;A PHASE 2 STUDY OF EFFICACY/SAFETY OF EVEROLIMUS IN SUBJECTS WITH IDIOPATHIC MYELOFIBROSIS (IMF);200.000,00;;; http://www.agenziafarmaco.gov.it/sites/default/files/49_VENTURA_ALESSANDRO.zip;FARM64J2EB;VENTURA ALESSANDRO ;IRCCS “Burlo Garofolo”;RANDOMIZED CONTROLLED DOUBLE-BLIND VS. PLACEBO MULTICENTRE STUDY ON THE SAFETY AND EFFECTIVENESS OF THALIDOMIDE IN THE TREATMENT OF REFRACTORY CROHN’S DISEASE AND ULCERATIVE COLITIS IN CHILDREN AND ADOLESCENTS;222.300,00;200.070,00;; http://www.agenziafarmaco.gov.it/sites/default/files/50_ZANETTI_ALESSANDRO.zip;FARM67NFPN;ZANETTI ALESSANDRO ;Università degli Studi di Milano;PERSISTENCE OF ANTI-HBs ANTIBODY AND OF IMMUNOLOGIC MEMORY FOR HEPATITIS B SURFACE ANTIGEN IN TWO COHORTS OF CHILDREN IMMUNISED WITH HEXAVALENT VACCINES: IMPLICATIONS FOR POLICY AND BOOSTER VACCINATION.;363.000,00;;;